Cormorant Asset Management, LP Vaxcyte, Inc. Transaction History
Cormorant Asset Management, LP
- $1.74 Billion
- Q1 2024
A detailed history of Cormorant Asset Management, LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 685,000 shares of PCVX stock, worth $51.7 Million. This represents 2.69% of its overall portfolio holdings.
Number of Shares
685,000
Previous 665,000
3.01%
Holding current value
$51.7 Million
Previous $41.8 Million
12.04%
% of portfolio
2.69%
Previous 2.51%
Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
269Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$735 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$718 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$579 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$371 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$313 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.48B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...